Work

Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps2619

Authors: Gerald Steven Falchook, Jayesh Desai, Ian M. Leitch, Jonathan Wade Goldman, Jennifer J. Wheler, Siqing Fu, Razelle Kurzrock, Megan Baldwin, Lee S. Rosen

Institutions: The University of Texas MD Anderson Cancer Center, The Royal Melbourne Hospital, University of California, Los Angeles, University of California San Diego

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2599361077

Cites:

Cited by:

Related to: 10